US Patent 11,690,842: Lumateperone Capsule Claims, Expiration, Orange Book Status and Generic Risk
US Patent 11,690,842 protects a specific oral capsule formulation of lumateperone mono-tosylate, not lumateperone generally. Its strongest claim elements are the crystalline mono-tosylate form, a narrow excipient system, rapid dissolution, particle-size controls, and pharmacokinetic performance. The patent is commercially relevant to Caplyta capsules, particularly the 42 mg free-base-equivalent strength.
The patent appears to be an Intra-Cellular Therapies formulation patent with a term extending into approximately 2039, subject to the patent’s full prosecution history, patent-term adjustment and any terminal disclaimer. It creates a meaningful formulation barrier for generic capsules but does not independently block all possible lumateperone products, alternative salts, non-capsule dosage forms, or formulations outside the claimed composition and performance ranges.
What does US Patent 11,690,842 protect?
The patent has three principal claim groups:
| Claim group |
Protected subject matter |
Commercial significance |
| Claims 1-13, 16-20 |
Lumateperone mono-tosylate capsule formulation |
Core product protection |
| Claim 14 |
Manufacturing process |
Manufacturing and process infringement risk |
| Claim 15 |
Therapeutic use of the capsule |
Method-of-use protection |
Independent claim 1 requires a pharmaceutical capsule containing:
- Lumateperone in mono-tosylate salt form;
- The salt in solid crystalline form;
- 10% to 30% by weight lumateperone mono-tosylate;
- 60% to 90% mannitol;
- 0.5% to 10% croscarmellose sodium;
- 0.1% to 1% talc;
- 0.1% to 3% magnesium stearate;
- A gelatin capsule; and
- Dissolution of at least 85% after 15 minutes, at least 92% after 30 minutes, and/or at least 94% after 45 minutes in 500 mL of 0.1N hydrochloric acid.
The claim therefore combines composition, dosage form, solid-state, manufacturing, and dissolution limitations. A generic product must avoid at least one required limitation to avoid literal infringement, although the doctrine of equivalents may remain relevant.
How narrow is claim 1?
Claim 1 is materially narrower than a conventional active-ingredient claim. A product must satisfy the following technical combination:
- The active ingredient must be lumateperone mono-tosylate.
- The salt must be crystalline.
- The dosage form must be a gelatin capsule.
- The formulation must use mannitol, croscarmellose sodium, talc and magnesium stearate within the stated ranges.
- The capsule must meet at least one stated dissolution threshold.
The use of "and/or" in the dissolution limitation is important. On its face, the claim may be satisfied if the product reaches any one of the three specified dissolution levels at the corresponding time point. A court could examine the specification and prosecution history to determine whether the limitation requires one or all of the stated performance criteria.
The claim also uses open-ended language in the formulation limitations. "Comprising" generally permits additional ingredients, but a product containing additional excipients would still risk infringement if the required ingredients and performance limitations are present.
What do the dependent claims add?
Dosage strengths and capsule colors
Claims 2-6 tie the formulation to commercially relevant dose levels and capsule appearance. Claim 6 specifically covers approximately 42 mg of lumateperone free base, corresponding to approximately 60 mg of lumateperone mono-tosylate.
This claim structure maps closely to the commercial 42 mg Caplyta product. Claims 3-5 also cover broader ranges equivalent to 1-60 mg free base, including 10-30 mg and 35-45 mg ranges.
The colorant claim does not protect color alone. It protects a gelatin capsule containing one or more listed colorants, including FD&C Yellow No. 6, FD&C Blue No. 1, FD&C Red No. 3, iron oxides and titanium dioxide.
Specific excipient compositions
Claims 7, 9 and 10 narrow the excipient system. Claim 9 recites approximately:
- 74% mannitol;
- 5% croscarmellose sodium;
- 0.3% talc; and
- 1% magnesium stearate.
Claim 10 recites approximately:
- 87% mannitol;
- 5% croscarmellose sodium;
- 0.3% talc; and
- 1.25% magnesium stearate;
- In a size 0 gelatin capsule.
These claims may provide stronger product-specific protection than claim 1 because they correspond more closely to a fixed commercial manufacturing formula. Their scope is also more vulnerable to design-around through changes to excipient quantities, capsule size or manufacturing formulation.
Crystal form and XRPD peaks
Claim 8 requires a crystalline lumateperone mono-tosylate exhibiting at least two XRPD peaks selected from the following values, each within ±0.2 degrees 2-theta:
5.68°, 12.11°, 16.04°, 17.03°, 18.16°, 19.00°, 21.67°, 22.55°, 23.48° and 24.30°.
The claim specifies copper-anode radiation with a nickel filter. This limitation creates a solid-state identification issue. Generic developers would need to characterize their lumateperone salt and assess whether the selected crystal form falls within the claimed diffraction pattern.
A polymorph or amorphous form that does not exhibit at least two of the listed peaks could provide a potential design-around. That route may be commercially difficult if the approved product’s bioavailability and manufacturability depend on the claimed crystalline material.
Particle-size limitations
Claims 13, 16 and 17 cover micronized or finely milled material. The narrowest limitations include:
- Mean particle size of 1-5 micrometers;
- D90 of 10 micrometers or less;
- D10 of 5 micrometers or less; and
- D50 of 2-5 micrometers.
Particle-size claims can be difficult to avoid if the active ingredient must be micronized to achieve the claimed dissolution profile. They also create measurement disputes involving sampling, dispersion medium, laser-diffraction settings and whether particle size is assessed before or after blending.
What does claim 14 protect?
Claim 14 covers a manufacturing process involving:
- Combining crystalline lumateperone mono-tosylate with mannitol;
- Blending;
- Optional filtration;
- Adding additional mannitol, croscarmellose sodium, talc and magnesium stearate;
- A second blending step;
- Optional filtration;
- Encapsulation into gelatin capsules; and
- Optional coating.
The process claim is significant because it protects a sequence rather than only the finished capsule. A generic manufacturer could face process infringement even if it attempts to characterize the final product differently, provided the accused manufacturing process performs the claimed steps.
The optional filtration steps do not appear to be required limitations. The required process path is the combination, first blend, excipient addition, second blend and encapsulation sequence.
What does claim 15 protect?
Claim 15 covers administration of the claimed capsule to treat or prevent diseases involving:
- 5-HT2A receptor signaling;
- Serotonin transporter signaling; and/or
- Dopamine D1/D2 receptor signaling.
The claim is broader in therapeutic language than a claim limited to one approved indication, but it remains tied to administration of the capsule of claim 1. It does not independently claim every use of lumateperone.
The practical value of claim 15 depends on the approved product label, generic labeling, prescribing information and the scope of any proposed skinny-label carveout. A generic applicant may attempt to omit patented indications, but a formulation claim such as claim 1 can still create a separate barrier.
When does US Patent 11,690,842 expire?
The patent’s expected ordinary term is approximately 20 years from the earliest effective nonprovisional priority date, subject to patent-term adjustment and any terminal disclaimer. Public patent records associate the patent family with an October 2018 priority period, which would place the unadjusted expiration date in approximately October 2039.
| Item |
Assessment |
| Patent |
US 11,690,842 |
| Patent owner |
Intra-Cellular Therapies, Inc. |
| Product relevance |
Lumateperone, marketed as Caplyta |
| Issue date |
June 27, 2023 |
| Earliest reported priority period |
October 2018 |
| Expected unadjusted term |
Approximately October 2039 |
| PTA/PTE effect |
Must be confirmed from the USPTO patent record |
| Core protection |
Crystalline lumateperone mono-tosylate capsule formulation |
The exact expiration date should be taken from the USPTO patent-term calculation and the patent’s continuity data. Patent issuance date is not the expiration-date determinant.
What is the Orange Book status of US 11,690,842?
US 11,690,842 is relevant to FDA-listed Caplyta products if it is included in the current Orange Book patent declaration for the applicable strengths and dosage forms. Orange Book listing should be checked by active ingredient, proprietary name, applicant and dosage form because FDA listings can change through delisting, corrections or new patent submissions.
The patent is more likely to be listed against the capsule dosage form than against a broad class of lumateperone products. An Orange Book listing would require an ANDA applicant to address the patent through certification under 21 U.S.C. § 355(j)(2)(A)(vii), including a Paragraph IV certification if the applicant contends that the patent is invalid, unenforceable or not infringed.
The patent’s formulation scope makes a Paragraph IV challenge commercially plausible. The challenger would likely argue that one or more of the following limitations is absent or invalid:
- The claimed crystalline salt was disclosed or obvious;
- The excipient combination was routine;
- The dissolution limitation lacks adequate distinction from prior art;
- Particle-size ranges were obvious optimization variables;
- The pharmacokinetic ranges are inherent or insufficiently limiting;
- The claim language is indefinite; or
- The claims lack written-description or enablement support across their full ranges.
What Paragraph IV challenges affect Caplyta?
A Paragraph IV filing against Caplyta would normally trigger Hatch-Waxman litigation if the NDA holder or patent owner brings suit within 45 days of receiving notice. A timely suit can impose a 30-month stay of ANDA approval, subject to statutory exceptions and court action.
The most commercially important distinction is between:
- A challenge to the basic lumateperone compound or salt;
- A challenge to crystalline-form patents;
- A challenge to capsule formulation patents such as US 11,690,842; and
- A challenge to method-of-use patents.
A generic applicant could succeed against one patent while remaining blocked by others. The relevant risk is therefore the full Orange Book estate, not US 11,690,842 in isolation.
Publicly available information should be checked for any pending district-court actions involving Intra-Cellular Therapies and ANDA applicants such as Teva, Sandoz, Lupin, Zydus or other generic manufacturers. The supplied record does not establish a final judgment, settlement or launch date for a Paragraph IV dispute involving this patent.
How strong is the patent estate for Caplyta?
The estate is strongest where several claim types overlap:
| Protection layer |
Risk to generic entrant |
| Active compound and salt |
High if unexpired and listed |
| Crystalline form |
High where the approved product uses the claimed form |
| Capsule formulation |
High for close copies of Caplyta |
| Particle size |
Moderate to high if needed for dissolution |
| Dissolution performance |
Moderate; may be difficult to prove from public ANDA data |
| Manufacturing process |
Moderate; discovery-intensive |
| Pharmacokinetic profile |
Moderate; may create testing and claim-construction issues |
| Method of use |
Moderate; depends on label and indication |
US 11,690,842 is not a complete substitute for compound protection. Its value is that it can maintain a barrier after a challenger defeats or avoids an earlier molecule patent. The combination of formulation and performance limitations also raises the cost of a straightforward capsule copy.
What generic launch scenarios exist?
Scenario 1: Certification and litigation
A generic applicant files an ANDA with a Paragraph IV certification. Intra-Cellular Therapies sues within 45 days. FDA approval is generally stayed for up to 30 months unless the litigation ends earlier or the court modifies the stay.
Scenario 2: Non-infringing formulation
The applicant changes the salt form, crystal form, excipient system, capsule material, particle-size distribution or dissolution profile. This approach reduces literal infringement risk but may create bioequivalence, stability or manufacturing problems.
Scenario 3: Paragraph III certification
The applicant accepts the patent and proposes approval after expiration. This delays launch but reduces litigation exposure.
Scenario 4: Settlement
The parties may agree to a licensed or otherwise authorized entry date. The commercial effect depends on the settlement’s date, scope, payment terms, supply provisions and potential Federal Trade Commission review.
Scenario 5: At-risk launch
A generic company launches before final resolution after obtaining approval or a favorable ruling. Exposure could include damages, an injunction and enhanced damages if infringement is found.
How does US 11,690,842 compare with other Caplyta protection?
US 11,690,842 is a product-formulation patent. It should be analyzed alongside earlier patents covering the lumateperone molecule, salt forms, crystalline forms, pharmaceutical compositions and therapeutic uses.
| Patent category |
Main question |
| Compound patent |
Is lumateperone itself still protected? |
| Salt patent |
Is mono-tosylate or another salt claimed? |
| Crystal patent |
Does the commercial solid match the claimed XRPD form? |
| Formulation patent |
Does the capsule meet the excipient and dissolution limitations? |
| Method-of-use patent |
Does the proposed label include a protected indication? |
| Process patent |
Does the generic use the claimed blending and encapsulation sequence? |
The commercial blocking position depends on the latest-expiring enforceable patent, not necessarily the patent with the broadest claims.
What revenue is exposed to generic competition?
Caplyta has become a major commercial product for Intra-Cellular Therapies. Company filings reported hundreds of millions of dollars in annual Caplyta net product sales, with growth driven by schizophrenia and bipolar depression use. The 42 mg strength is particularly important because it corresponds to the principal commercial dose and is directly addressed by claims 3-6 and 18-20.
A generic entrant targeting the 42 mg capsule would face the highest immediate commercial opportunity and the greatest risk of reading on the patent’s dosage, composition and pharmacokinetic claims.
Key Takeaways
- US 11,690,842 protects a crystalline lumateperone mono-tosylate gelatin capsule with specified excipients and dissolution performance.
- The patent directly covers formulation attributes associated with Caplyta, especially the 42 mg free-base-equivalent dose.
- Claims 8, 13, 16 and 17 add crystalline-form and particle-size barriers that may be difficult to design around without affecting bioavailability.
- Claim 14 creates process-infringement exposure for manufacturers using the claimed blending and encapsulation sequence.
- The patent’s expected term extends to approximately 2039, subject to USPTO term calculations and continuity details.
- A generic challenger would need to address the entire Caplyta Orange Book estate, not this patent alone.
- The principal invalidity and non-infringement pressure points are crystal-form disclosure, dissolution testing, particle-size measurement, pharmacokinetic limitations, claim indefiniteness and formulation design-around.
- Claims 9 and 10 warrant special scrutiny because the stated fixed excipient percentages, combined with a 10%-30% active range, can create aggregate-percentage and claim-construction issues.
FAQs
Does US 11,690,842 cover all lumateperone products?
No. It is directed to a specific crystalline mono-tosylate capsule formulation, its manufacturing process and administration of that capsule.
Can a generic avoid US 11,690,842 by using a tablet?
Potentially. A tablet would not literally satisfy the gelatin-capsule limitation, although other Caplyta patents could still apply.
Does changing mannitol content avoid the patent?
It may avoid literal infringement of a composition claim if the formulation falls outside the claimed range. The generic product would still need to assess other patents and the doctrine of equivalents.
Why are the pharmacokinetic claims commercially important?
Claims 18-20 connect the formulation to Cmax, Tmax and AUC ranges after fasting administration. They can make a close bioequivalent product easier to challenge, but proving infringement may require clinical or pharmacokinetic evidence.
Are biosimilars relevant to lumateperone?
No. Lumateperone is a synthetic small-molecule drug, so the relevant competitors are ANDA-based generics, not biosimilars under the Public Health Service Act.
References
-
U.S. Patent No. 11,690,842. (2023). Pharmaceutical compositions comprising lumateperone. United States Patent and Trademark Office.
-
U.S. Food and Drug Administration. (n.d.). Caplyta (lumateperone) prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
-
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions: Refusal to receive guidance for industry. FDA.
-
Intra-Cellular Therapies, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
-
United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term information. USPTO.
